证券日报网讯12月4日，新华医疗（600587）在互动平台回答投资者提问时表示，公司已发布减持公 告，自新华医疗董事会决议之日起12个月内，华佗国际通过公开市场交易方式减持华检医疗不超过5% 股份。 ...

Group 1 - The core viewpoint of the article is that Xinhua Medical is considering stock repurchase and cancellation based on various factors including future business plans and financial conditions [1] - The company will strictly adhere to information disclosure rules if there are any related arrangements in the future [1]

Core Viewpoint - The stock of Xinhua Medical (600587) has shown a slight increase, with a closing price of 15.04 yuan on December 4, 2025, reflecting a 0.33% rise, while the company faces declining revenue and profit trends in its recent financial performance [1][3]. Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main business revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [3]. - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year, while the net profit after deducting non-recurring gains and losses was 370 million yuan, a decline of 38.98% [3]. - In Q3 2025, the company recorded a single-quarter main business revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year, and a net profit of approximately 48.59 million yuan, down 63.39% year-on-year [3]. Market Position and Ratios - Xinhua Medical's total market value is 9.124 billion yuan, which is below the industry average of 10.958 billion yuan, ranking 40th out of 124 in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 15.76, significantly lower than the industry average of 60.57, ranking 5th in the industry [3]. - The gross profit margin stands at 25.11%, which is considerably lower than the industry average of 51.22%, ranking 111th out of 124 [3]. Investment Sentiment - In the last 90 days, two institutions have given a rating of "buy" for Xinhua Medical, with an average target price of 20.0 yuan [4].

Core Viewpoint - The company is progressing with the development of its lower limb exoskeleton robot, which is currently in the prototype stage and is expected to complete product development by 2026 and obtain medical device registration by 2027 [1]. Group 1 - The company has received a notice of acceptance for its patent application from the National Intellectual Property Administration for the lower limb assistive exoskeleton robot, which is set to undergo clinical trials [1]. - The product is designed for multiple application scenarios, including hospitals, communities, homes, and elderly care institutions [1]. - The expected timeline for the completion of product development is 2026, with medical device registration anticipated in 2027 [1].

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

每经AI快讯，有投资者在投资者互动平台提问：请问在外骨骼机器人方面，公司对发展前景如何看 待？投入情况和取得成果，请简单介绍下。 （文章来源：每日经济新闻） 新华医疗（600587.SH）12月4日在投资者互动平台表示，随着国内人口老龄化程度的不断加深，康复 需求持续增长，下肢外骨骼康复机器人作为康复机器人市场的重要组成部分，其市场份额也在不断扩 大。近年来，随着医疗行业的快速发展，国家出台了一系列政策、法律和法规，也为下肢外骨骼康复机 器人的发展提供了重要的政策支持和保障。公司高度重视外骨骼机器人的发展，已组建涵盖机械、控 制、康复医学等多学科的专业研发团队，并持续投入研发资源。截至目前，已在外骨骼结构轻量化、关 节驱动控制、步态轨迹生成等关键技术上实现突破，为产品化奠定了扎实基础。 ...

格隆汇12月4日丨新华医疗(600587.SH)在投资者互动平台表示，新华医疗目前无回购计划。 ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：大盘即将站上4000点。公司在4000点回购是不是认为 风险太大？ 新华医疗（600587.SH）12月4日在投资者互动平台表示，新华医疗目前无回购计划。 ...

Core Viewpoint - The company has received a patent application acceptance notice for its lower limb exoskeleton robot, indicating progress in its product development timeline [1] Group 1: Product Development - The lower limb exoskeleton robot is currently in the functional prototype development stage, with an expected completion of product development by 2026 [1] - The company aims to obtain the medical device registration certificate by 2027, allowing for broader market entry [1] Group 2: Application Scenarios - The exoskeleton robot is designed for multiple application scenarios, including hospitals, communities, homes, and elderly care institutions [1]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-063 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）和控股 子公司新华手术器械有限公司于近日收到山东省药品监督管理局颁发的《中华人民 共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 （一）手术无影灯 1、产品名称：手术无影灯 2、注册证编号：鲁械注准 20252010721 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：产品由灯头、悬臂组件和安装固定组件组成。其中安装固定 组件包括基座和下延柱，悬臂组件包括横譬和弹簧臂，灯头包括上弯管、下弯管、 灯头主体、可拆卸手柄和臂控面板。 7、型号、规格： SMart-L80plus/L80plus/L80plus、SMart-L80p ...